DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 4,786,599
|Title:||Serum-free animal cell culture medium and methods for the primary culture and production of cell lines using this medium|
|Abstract:||A serum-free animal tissue culture medium contains a mixture of six fatty acids and albumin or dextran. The medium is particularly adapted for the primary culture of rat liver epithelial cells and possibly in the presence of hormones and/or growth factors, for obtaining cell lines, in particular of myelomae and hybridomae.|
|Inventor(s):||Chessebeuf; Martina L. (Dijon, FR), Padieu; Prudent H. (Chevigny St Sauveur, FR)|
|Assignee:||Institut National de la Sante et de la Recherche Medicale (Paris, FR)|
|Patent Claims:||1. Serum-free animal cell culture medium, characterized in that is consists essentially of:
(a) a synthetic basal medium designed for animal cell culture;
(b) 0.05 to 30 .mu.eq/l of a mixture of the six fatty acids palmitic acid, cis-palmitoleic acid, stearic acid, cis-oleic acid, cis-linoleic acid and cis-linolenic acid or their esters, in the following proportions, relative to the free fatty acid:
from 0.0155 to 24.0 .mu.mole/l of palmitic acid;
from 0.0058 to 9.0 .mu.mole/l of cis-palmitoleic acid;
from 0.0014 to 2.0 .mu.mole/l of stearic acid;
from 0.0067 to 10.0 .mu.mole/l of cis-oleic acid;
from 0.0178 to 27.0 .mu.mole/l of cis-linolenic acid; and
from 0.0028 to 4.0 .mu.mole/l of cis-linolenic acid, adsorbed on
(c) at least one water-soluble lipophile biopolymer present in an amount capable of ensuring the dissolution of the fatty acids or esters present in the medium.
2. Culture medium according to claim 1, wherein the mixture is of said six fatty acids are present therein in the free acid state.
3. Culture medium according to claim 1, wherein the synthetic basal medium is selected from the group consisting of:
Waymouth MB 752/1 medium
RPMI 1629 or 1640 media
modified Eagle media
Williams E medium
medium 199 and derived media of the types
4. Culture medium according to claim 1, wherein said antibiotic has a wide spectrum.
5. Culture medium according to claim 1, wherein said antibiotic is gentamicin in the proportion of 25 to 100 mg/l.
6. Culture medium according to claim 1, wherein the water soluble lipophile biopolymer is constituted by lipid-free or not lipid-free albumin or by a dextran.
7. Culture medium according to claim 6, wherein the albumin is present in an amount of 2 to 6 g/l of culture medium.
8. Culture medium according to claim 6, wherein the dextran is present in an amount from 0.5 to 200 mg/l of culture medium.
9. Process for obtaining a cell line using the culture medium according to claim 1, which consists of:
(a) subjecting to enzymatic digestion the cellular product of a prior culture, to initiate one or several secondary culture(s),
(b) carrying out the one or more secondary culture(s) in the culture medium, and
(c) repeating steps (a) and (b) with the cellular product of the preceding step (b) as many times as necessary to preserve the cell line during the desired time.
10. Process for obtaining a cell line according to claim 9, wherein the cellular product results of a prior culture which as reached confluency.
11. Culture medium according to claim 1 further including an antibiotic in non-cytotoxic concentration throughout the passage of the culture.
12. Culture medium according to claim 1 further including at least one compound selected from hormones and growth factors.
13. Culture medium according to claim 12 further including an antibiotic in non-cytotoxic concentration throughout the passage of the culture.
14. A process for obtaining a cell line using the culture medium according to claim 13, which consists essentially of:
(a) suspending cells of a prior culture in the said culture medium;
(b) carrying out the culture of the cells in the said culture medium; and
(c) repeating steps (a) and (b) as many times as necessary to preserve the cell line during the desired time.
15. Process for the primary culture of rat liver epithelial cells using the culture medium according to claim 1, characterized in that it consists essentially of:
(1) taking up the tissue containing the cells to be cultivated and mincing it very finely, in a basal culture medium, not containing Ca.sup.2+ and Mg.sup.2+ ions, warmed (30.degree.-37.degree. C.), under aseptic conditions;
(2) after rinsing, in the basal medium not containing Ca.sup.2+ and Mg.sup.2+ ions, subjecting the tissue to a sequential enzymatic digestion,
(3) transferring the suspension of cells thus released into a basal culture medium, centrifuging while following in parallel the digestion of the remaining tissue in step 2,
(4) placing the centrifugation pellet in suspension in the culture medium then,
(5) inoculating the suspension so obtained on the culture substratum previously or simultaneously surfacted,
(6) incubating in an air-tight incubator, saturated with water vapour, in the presence of a nitrogen, oxygen, and carbon dioxide mixture at 76%:19%:5%, while renewing the culture medium periodically,
steps (3) to (6) being repeated on the different fractions of dissociated desired cells, obtained sequentially at step (2), using each time a new culture substratum.
16. A process according to claim 15 wherein, in step (4), the culture medium contains a surface coating agent for the culture substratum.
17. Process of primary culture of rat liver epithelial cells according to claim 15, characterized in that the enzymatic digestion is carried out by means of collagenase or trypsin.
18. Process of primary culture of rat liver epithelial cells according to claim 15, characterized in that the surfacting of the substratum is carried out by means of serum, collagen, polylysine or fibronectine.
19. Process according to claim 18, wherein the surface coating agent of the substratum is fetal calf serum, newborn calf serum or fibronectin.
20. Process of primary culture of rat liver epithelial cells according to claim 15, wherein the basal culture medium is that used in the preparation of the culture medium of step (4).
Summary for Patent: ⤷ Free Forever Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|France||83 04843||Mar 24, 1983|
|PCT Filed||March 23, 1984||PCT Application Number:||PCT/FR84/00080|
|PCT Publication Date:||September 27, 1984||PCT Publication Number:||WO84/03710|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Smith And Nephew||SANTYL||collagenase||OINTMENT;TOPICAL||101995||001||1965-06-04||⤷ Free Forever Trial||Institut National de la Sante et de la Recherche Medicale (Paris, FR)||2005-11-22||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|Germany||3477583||⤷ Free Forever Trial|
|European Patent Office||0136353||⤷ Free Forever Trial|
|France||2543158||⤷ Free Forever Trial|
|Japan||S60500748||⤷ Free Forever Trial|
|World Intellectual Property Organization (WIPO)||8403710||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.